Biosynthesis is nature’s chemistry. Engineering biosynthesis is learning from nature and reproducing them inside a laboratory setting.
InMed Pharmaceuticals is developing a unique platform to produce cannabinoids in the laboratory.
We are taking the genetics of the cannabis plant, inserting that into microorganisms. This leads to the production of bioidentical, high purity high-grade cannabinoids. My laboratory has extensive experience in working with a variety of microbial.
The hosts that we select for InMed’s process is been suited to produce molecules. It outperforms traditional systems such as yeast. It is able to make these molecules at high titers and high productivity. Think of cannabinoid biosynthesis as a collection of lego blocks.
Learn more about InMed Pharma
You can make a variety of shapes by piecing together these different pieces of lego. So now what our platform allows us to do, is to piece these different building blocks together. And produce unique biosynthetic pathways leading to the production of an unprecedented molecules. The success of a research team is dependent on the untiring efforts. Any biomanufacturing process is dependent on three vital pieces. We have been working with InMed Pharmaceuticals for three years to get the ideal strain. Resulting in exhibiting the highest productivity. We will be working on bioprocess engineering to design the ideal process. It gives us a competitive advantage that will make a difference in patients lives.
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
For more information on InMed Pharmaceuticals (IN:TSX,IMLFF:OTCQX) please fill out the form below